Halozyme Therapeutics (NASDAQ: HALO)
|Date||Analyst Firm||Analyst Name||Action||Rating||Action Price||Prior Price||Target|
You can purchase shares of Halozyme Therapeutics (NASDAQ: HALO) through any online brokerage.
The latest price target for Halozyme Therapeutics (NASDAQ: HALO) was reported by Goldman Sachs on Thursday, May 26, 2022. The analyst firm set a price target for 60.00 expecting HALO to rise to within 12 months (a possible 34.89% upside). 5 analyst firms have reported ratings in the last year.
The stock price for Halozyme Therapeutics (NASDAQ: HALO) is $44.48 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Halozyme Therapeutics.
Halozyme Therapeutics’s Q2 earnings are confirmed for Monday, August 8, 2022.
There is no upcoming split for Halozyme Therapeutics.
Halozyme Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.